Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation

The farnesoid X receptor (FXR) is involved in glucose and lipid metabolism regulation, which makes it an attractive target for the metabolic syndrome, dyslipidemia, atherosclerosis, and type 2 diabetes. In order to find novel FXR agonists, a structure-based pharmacophore model collection was develop...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioorganic & medicinal chemistry 2011-12, Vol.19 (23), p.7168-7180
Hauptverfasser:	Schuster, Daniela, Markt, Patrick, Grienke, Ulrike, Mihaly-Bison, Judit, Binder, Markus, Noha, Stefan M., Rollinger, Judith M., Stuppner, Hermann, Bochkov, Valery N., Wolber, Gerhard
Format:	Artikel
Sprache:	eng
Schlagworte:	Binding Sites Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Drug Design Farnesoid X receptor FXR agonist General and cellular metabolism. Vitamins HEK293 Cells Humans Lead identification Medical sciences Models, Molecular Molecular modeling Pharmacology. Drug treatments Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - chemistry Receptors, Cytoplasmic and Nuclear - metabolism Structure-Activity Relationship Virtual screening
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!